Cardiac Involvement in Granulomatosis with Polyangiitis

REFERENCES

1. 1.↵
   1. Walsh M,
   2. Flossmann O,
   3. Berden A,
   4. Westman K,
   5. Hoglund P,
   6. Stegeman C,
   7. et al.

   Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012;64:542–8.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Guillevin L,
   2. Pagnoux C,
   3. Seror R,
   4. Mahr A,
   5. Mouthon L,
   6. Toumelin PL

   . The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 2011;90:19–27.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Miszalski-Jamka T,
   2. Szczeklik W,
   3. Sokolowska B,
   4. Miszalski-Jamka K,
   5. Karwat K,
   6. Grzadziel G,
   7. et al.

   Cardiac involvement in Wegener’s granulomatosis resistant to induction therapy. Eur Radiol 2011;21:2297–304.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Morelli S,
   2. Gurgo Di Castelmenardo AM,
   3. Conti F,
   4. Sgreccia A,
   5. Alessandri C,
   6. Bernardo ML,
   7. et al.

   Cardiac involvement in patients with Wegener’s granulomatosis. Rheumatol Int 2000;19:209–12.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Oliveira GH,
   2. Seward JB,
   3. Tsang TS,
   4. Specks U

   . Echocardiographic findings in patients with Wegener granulomatosis. Mayo Clin Proc 2005;80:1435–40.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Koldingsnes W,
   2. Nossent JC

   . Baseline features and initial treatment as predictors of remission and relapse in Wegener’s granulomatosis. J Rheumatol 2003;30:80–8.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Pierrot-Deseilligny Despujol C,
   2. Pouchot J,
   3. Pagnoux C,
   4. Coste J,
   5. Guillevin L

   . Predictors at diagnosis of a first Wegener’s granulomatosis relapse after obtaining complete remission. Rheumatology 2010;49:2181–90.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Leavitt RY,
   2. Fauci AS,
   3. Bloch DA,
   4. Michel BA,
   5. Hunder GG,
   6. Arend WP,
   7. et al.

   The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990;33:1101–7.

   OpenUrlPubMed
9. 9.↵
   Minitab 16.1 Statistical Software [computer software]. State College, Pennsylvania: Minitab Inc.
10. 10.↵
    1. Holle JU,
    2. Dubrau C,
    3. Herlyn K,
    4. Heller M,
    5. Ambrosch P,
    6. Noelle B,
    7. et al.

    Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2012;71:327–33.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Faurschou M,
    2. Mellemkjaer L,
    3. Sorensen IJ,
    4. Svalgaard Thomsen B,
    5. Dreyer L,
    6. Baslund B

    . Increased morbidity from ischemic heart disease in patients with Wegener’s granulomatosis. Arthritis Rheum 2009;60:1187–92.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Morgan MD,
    2. Turnbull J,
    3. Selamet U,
    4. Kaur-Hayer M,
    5. Nightingale P,
    6. Ferro CJ,
    7. et al.

    Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 2009;60:3493–500.

    OpenUrlCrossRefPubMed